Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Non-Current Liabilities (2016 - 2022)

Spero Therapeutics' Total Non-Current Liabilities history spans 7 years, with the latest figure at $48.9 million for Q4 2022.

  • For Q4 2022, Total Non-Current Liabilities fell 40.39% year-over-year to $48.9 million; the TTM value through Dec 2022 reached $48.9 million, down 40.39%, while the annual FY2022 figure was $48.9 million, 40.39% down from the prior year.
  • Total Non-Current Liabilities reached $48.9 million in Q4 2022 per SPRO's latest filing, up from $32.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $83.4 million in Q1 2022 to a low of $5.9 million in Q1 2018.
  • Average Total Non-Current Liabilities over 5 years is $29.2 million, with a median of $19.3 million recorded in 2019.
  • Peak YoY movement for Total Non-Current Liabilities: soared 3450.5% in 2018, then plummeted 40.39% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $12.9 million in 2018, then soared by 49.1% to $19.3 million in 2019, then surged by 41.46% to $27.3 million in 2020, then soared by 200.66% to $82.0 million in 2021, then tumbled by 40.39% to $48.9 million in 2022.
  • Per Business Quant, the three most recent readings for SPRO's Total Non-Current Liabilities are $48.9 million (Q4 2022), $32.0 million (Q3 2022), and $27.6 million (Q2 2022).